Research Article

Cost-Effectiveness of Catheter Ablation for Rhythm Control of Atrial Fibrillation

Gord Blackhouse,1,2 Nazila Assasi,1,2 Feng Xie,1,2,3 Kathryn Gaebel,1,3 Kaitryn Campbell,1,2 Jeff S. Healey,4 Daria O’Reilly,1,2,3 and Ron Goeree1,2,3

1 PATH Research Institute, McMaster University, Suite 2000, 25 Main Street West, Hamilton, ON, Canada L8P 1H1
2 Department of Clinical Epidemiology & Biostatistics, McMaster University, Hamilton, ON, Canada L8S 4L8
3 Centre for Evaluation of Medicines, St. Joseph’s Healthcare, Hamilton, ON, Canada L8P 1H1
4 Population Health Research Institute, McMaster University, Hamilton, ON, Canada L8L 2X2

Correspondence should be addressed to Gord Blackhouse; blackhou@mcmaster.ca

Received 31 January 2013; Revised 28 June 2013; Accepted 13 July 2013

Academic Editor: John A. Kern

Copyright © 2013 Gord Blackhouse et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. The objective of this study is to evaluate the cost-effectiveness of catheter ablation for rhythm control compared to antiarrhythmic drug (AAD) therapy in patients with atrial fibrillation (AF) who have previously failed on an AAD. Methods. An economic model was developed to compare (1) catheter ablation and (2) AAD (amiodarone 200 mg/day). At the end of the initial 12 month phase of the model, patients are classified as being in normal sinus rhythm or with AF, based on data from a meta-analysis. In the 5-year Markov phase of the model, patients are at risk of ischemic stroke each 3-month model cycle. Results. The model estimated that, compared to the AAD strategy, ablation had $8,539 higher costs, 0.033 fewer strokes, and 0.144 more QALYS over the 5-year time horizon. The incremental cost per QALY of ablation compared to AAD was estimated to be $59,194. The probability of ablation being cost-effective for willingness to pay thresholds of $50,000 and $100,000 was estimated to be 0.89 and 0.90, respectively. Conclusion. Based on current evidence, pulmonary vein ablation for treatment of AF is cost-effective if decision makers willingness to pay for a QALY is $59,194 or higher.

1. Background

Atrial fibrillation (AF) is the most common form of cardiac arrhythmia, associated with high morbidity and mortality. Based on the estimate of the Heart and Stroke Foundation, AF affects approximately 250,000 Canadians [1, 2]. This condition is characterized by disorganized, rapid, and irregular activity of the two upper chambers of the heart (atria), associated with irregular and rapid response of the two lower chambers of the heart (ventricles). Patients with AF are at higher risk of clot formation and subsequent adverse hemodynamic events such as stroke. AF increases the risk of stroke four- to five-fold across all age groups and is responsible for 10%–15% of all ischemic strokes [3]. The rate of hospitalization for AF in Canada was approximately 583 per 100,000 people, between 1997 and 2000, with an average of 129,000 hospitalizations per year [4].

AF may be classified on the basis of electrocardiographic findings or the frequency of episodes and the ability of an episode to convert back to sinus rhythm. AF is classified as a first-detected episode or a recurrent episode. Recurrent AF can be subclassified as paroxysmal (self-terminating, usually <24 hours), persistent (sustained >7 days), or permanent [5].

There are two main strategies for AF treatment: rhythm control (cardioversion and maintenance of sinus rhythm with antiarrhythmic drugs (AADs)) and rate control (atrioventricular (AV) nodal blockers and anticoagulation). The Canadian Cardiovascular Society (CCS) recommends both strategies as acceptable initial approaches. The only exception is for permanent AF, where rate control is recommended [6]. Various treatment options are available for rhythm control including medication, electrical (direct-current) cardioversion, or surgical procedures [7]. AAD therapy is recommended as a first choice for restoration of normal sinus
rhythm (NSR) [7]. Three Class I drugs (flecainide, quinidine, and propafenone) and two Class III drugs (sotalol and amiodarone) are commonly used in Canada for treatment of AF [8]. Due to the limitations of these drugs in maintenance of NSR, along with side effects, nonpharmacological approaches including catheter ablation have been recently considered in treatment of AF [7, 9, 10]. The current standard surgical treatment is the Cox-Maze procedure, which requires open heart surgery [11, 12]. Because of the invasive nature of the Cox-Maze procedure, minimally invasive catheter-based interventions have been developed [13].

The goals of catheter ablation procedures are to eliminate triggers of AF and to modify the atrial substrate(s) responsible for the maintenance of AF [14]. Given that the pulmonary veins (PV) represent a critical anatomic site for the treatment of AF [15], minimally invasive procedures often involve the isolation of the source of abnormal impulses originating from these veins. In a minimally invasive catheter ablation procedure, a catheter is inserted through the femoral vein to access the heart and burn abnormal foci of electrical activity by direct contact or by isolating them from the rest of the cardiac atrium. Radiofrequency energy is most commonly used for AF ablation [16].

Antiarrhythmic drug therapy presents the advantage of being a noninvasive and commonly available therapeutic option but it may require chronic administration. Ablation of AF is associated with larger upfront costs but may be more successful in maintaining normal sinus rhythm over time. Therefore, there may be a trade-off between higher costs and better outcomes with AF ablation compared to antiarrhythmic medications. The objective of this paper is to assess the cost-effectiveness of treating paroxysmal AF patients with catheter ablation compared to antiarrhythmic drug treatment.

2. Methods

2.1. Overview. A Canadian specific cost-effectiveness analysis was conducted using a combined decision tree and Markov model for patients with AF. The treatment comparators in the model are (1) AF catheter ablation and (2) antiarrhythmic drug treatment (amiodarone 200 mg per day). The starting population are 65-year-old males with paroxysmal AF previously unsuccessfully treated with an AAD. Patients are assumed to have a CHADS2 [17] stroke risk score of 2. The CHADS2 index predicts the annual probability of stroke for individuals based on a risk score ranging from 0 to 6. This assumption is based on the mean CHADS2 score (2.1) amongst participants in the National Registry of Atrial Fibrillation [17]. The analysis was taken from the perspective of a publicly funded health care system. In the basecase analysis, the time horizon of the model was set to five years with a cycle length of three months. Although the clinical impact of AF treatment may go beyond five years, this time horizon was chosen due to the short-term nature (i.e., 12 months) of the randomized clinical trials comparing AF ablation with AAD. Alternate time horizons were tested in a sensitivity analysis.

2.2. Model Structure. The model is comprised of both a one-year decision tree and a longer-term Markov model. Figures 1 and 2 graphically present the structure of the short-term and long-term models, respectively. As shown in Figure 1, a proportion of patients undergoing ablation are at risk of operative complications. These include cardiac tamponade, pulmonary vein stenosis, ischemic stroke, and transient ischemic attack. Patients suffering stroke are assumed to incur a permanent disability. Patients without an operative complication or with a nonstroke complication end the short-term model either in normal sinus rhythm (NSR) or with atrial fibrillation (AF). Patients in the AAD treatment group follow similar pathways as AF ablation patients during the one-year model. AAD patients are not at risk of operative complications but are at risk of pulmonary toxicity, which can be fatal, reversible, or irreversible. The proportion of patients in NSR after one year is based on freedom of AF outcomes from randomized controlled trials (RCTs) comparing AF ablation with AADs.

Figure 2 presents the structure of the long-term Markov model. Patients who are alive and not suffering a stroke after the one-year model enter the Markov model in either the NSR health state or the AF health state. In each three-month model cycle, patients are at risk of ischemic stroke and major bleeding events due to concomitant anticoagulants. The risk of stroke differs between patients in the NSR and AF health states. AF ablation patients are assumed to discontinue warfarin three months after their procedure, resulting in different bleeding risks between AF ablation patients and AAD treated patients. A proportion of major bleeds are intracranial haemorrhages (ICH). For simplicity, the remainder of the major bleeds is assumed to be gastrointestinal.

Patients in the AF ablation treatment arm who do not achieve normal sinus rhythm after 1 year or have a subsequent recurrence of AF are assumed to switch to AAD treatment. Patients in the AAD treatment arm who do not achieve normal sinus rhythm after 1 year or have a subsequent recurrence of AF are assumed to remain on AAD treatment. There are separate health states to distinguish between the first and subsequent years after ischemic stroke and ICH. In every three-month cycle, patients in the NSR health state can revert back to the AF health state. Each health state is associated with different costs, utilities, and mortality rates.

2.3. Clinical Parameters. Various clinical model input parameters were used to populate the model. These parameters were used to estimate the expected QALYs and the expected number of strokes for each treatment group. These include the probability of achieving NSR for each treatment group; the probability of ischemic stroke; the probability of major bleeding; the probability of reverting to AF after achieving NSR; the probability of AF ablation procedural complications; the probability of pulmonary toxicity while being on an AAD; utility values for the various health states; mortality associated with the various health states. Data from a systematic review conducted as part of a health technology assessment on AF ablation was used to estimate the probability of normal sinus rhythm 12 months after ablation or antiarrhythmic treatment. Targeted reviews were
undertaken to identify studies addressing the other clinical model variables.

2.4. Normal Sinus Rhythm at 1 Year. The probability of being in normal sinus rhythm at one year was derived from data presented in a systematic review conducted by Assasi et al. [18]. In this systematic review, the authors identified five RCTs [19–23] that evaluated the proportion of patients in normal sinus rhythm 12 months after receiving either AF ablation or second-line ant-arrhythmic therapy. For the AAD treatment strategy, the probability of being in NSR after one year was estimated by pooling data from the AAD arms of these five RCTs using random effects meta-analysis [24]. The pooled probability of being in NSR at 12 months for the AAD treatment arm was estimated to be 0.26 (95% CI: 0.17, 0.34). Table 1 provides the proportion of AAD in NSR at one year for each of these studies.

Assasi et al. [18] reported the relative risk of being in NSR at 12 months for AF ablation patients compared to AAD patients to be 2.93 (2.09, 4.11) in five RCTs of previous AAD failures. Based on this relative risk and the probability of being in NSR for the AAD treatment arm, the probability of AF

Table 1: Studies used to estimate probability of being in NSR at 1 year for AAD.

| Study                      | n  | n NSR at 12 months | Proportion NSR at 12 months | Weight of study |
|----------------------------|----|--------------------|-----------------------------|-----------------|
| Forleo et al. (2009) [19]  | 35 | 15                 | 0.43                        | 15.5%           |
| Jais et al. (2008) [20]    | 55 | 13                 | 0.24                        | 22.4%           |
| Pappone et al. (2006) [22] | 99 | 22                 | 0.22                        | 27.6%           |
| Krittayaphong et al. (2003) | 15 | 6                  | 0.40                        | 8.8%            |
| Wilber et al. (2010) [23]  | 61 | 10                 | 0.16                        | 25.7%           |

Pooled 0.26 (95% CI: 0.17, 0.34).
ablation patients being in NSR at one year was estimated to be 0.756 (2.93 × 0.26).

2.5. Probability of Ischemic Stroke. The annual probability of ischemic stroke for patients while in the AF health state was based on the CHADS₂ classification system published by Gage et al. [17]. The probability of stroke by CHADS₂ score [17] was estimated using a US registry of patients with AF. The CHADS₂ stroke probabilities were applied to patients while being in the AF health state of the model. A CHADS₂ risk score of 2, which corresponds to an annual risk of stroke 0.04, was assumed in the basecase analysis. In sensitivity analysis, the model is run assuming different risk scores.

A post hoc study [25] investigating the risk factors for ischemic strokes amongst patients enrolled in the AFFIRM trial [18] found that patients with AF had a 1.6 times greater risk of stroke than patients who were in normal sinus rhythm after treatment. Therefore, patients with normal sinus rhythm were assumed to have a relative risk reduction of stroke compared to patients with AF of 1/1.6, which is equal to 0.625. For example, if patients with AF are assumed to have a 0.04 annual risk of stroke, patients in normal sinus rhythm would be assumed to have an annual risk of stroke of 0.04 × 0.625, which is equal to 0.025. In sensitivity analysis, the model is run assuming that being in normal sinus rhythm has no impact on stroke risk.

2.6. Major Bleeds. It is assumed that the proportion of patients taking warfarin in both treatment groups entering the model was 0.44 [26]. This was based on the percentage of patients in the FRAXATIONAL registry that remained long term users of warfarin therapy after being diagnosed with atrial fibrillation [26]. The probability of bleeding while being on warfarin and aspirin therapy was based on data presented in a systematic review and meta-analysis published by Lip and Edwards [27]. First, the annual risk of major bleed while not receiving either warfarin or aspirin therapy was estimated based on details reported for the placebo arms of the studies included in the systematic review. These details included the number of patients and number of major bleeds in the placebo arm of each included study along with the mean duration of each study. Based on this data, the annual rate of a major bleed in the absence of warfarin or aspirin therapy was estimated to be 0.0058.

Lip and Edwards [27] reported the relative risk of a major bleed for placebo compared to warfarin to be 0.45 (95% CI 0.25, 0.82). This relative risk was applied to the rate of major bleed without warfarin therapy to estimate the annual probability of major bleed while on being warfarin therapy. The annual probability of major bleed while being on warfarin therapy was estimated to be 0.0129 (0.00458 × 1/0.45).

Data from the Stroke Prevention in Atrial Fibrillation II Study [28, 29] were used to estimate the proportion of major bleeds that are ICHs. The annual rate of major haemorrhages along with the annual rate of ICH for patients on aspirin and warfarin therapy was presented. Based on this data, the proportion of major bleeds that are ICHs was estimated to be 0.332.

2.7. Recurrence of Atrial Fibrillation. The probability of recurrence of AF after achieving NSR was derived from a long-term observational study of AF ablation and AAD treatment by Pappone et al. [30] who reported the probability of being free of AF at one, two, and three years for both AAD and ablation treated patients. Based on the one- and three-year data, the annual probability of AF recurrence for patients achieving NSR was estimated to be 0.036 for AF ablation treated patients and 0.221 for AAD treated.

2.8. Procedural Complications and Adverse Events. The probability of AF ablation procedural complications was taken from a systematic review of RCT and non-RCT studies evaluating catheter-based AF ablation procedures [31]. The probabilities of ischemic stroke, transient ischemic attack, cardiac tamponade, and pulmonary veins stenosis resulting from AF ablation are 0.003, 0.002, 0.008, and 0.016, respectively.

The probability of pulmonary toxicity while being on AAD treatment was based on data presented by Vorperian et al. [32]. Vorperian et al. [32] performed a meta-analysis for adverse events while being on low dose amiodarone. The authors report that 1.9% of amiodarone patients from their four included studies suffered from pulmonary toxicity. Based on the weighted mean followup in the studies (27.54 months), the annual probability of pulmonary toxicity was estimated to be 0.00832. The proportion of cases of pulmonary toxicity that are irreversible was assumed to be 0.25 [33]. The probability of death following pulmonary toxicity was assumed to be 0.091 as reported by Dusman et al. [34].

2.9. Mortality. General population age and gender specific mortality rates based on Canadian Life Tables [35, 36] were applied to patients in the model in the absence of events (e.g., ischemic stroke and major bleeds). Several sources were used to derive mortality rates for patients who suffer an ischemic stroke during the model. Johansen et al. [37] reported various outcomes for 34,448 patients hospitalized for first stroke in Canada. Amongst the outcomes reported were 28-day mortality rates by age group and gender according to stroke type. The 28-day mortality rates for patients with strokes classified as cerebral infraction (ICD-9 434,436) were applied to patients suffering an ischemic stroke in the model. To account for the increased risk of death following the remainder of the first year after stroke, data from another Canadian-based publication was used. Tu and Gong [38] reported mortality for patients hospitalized for acute stroke in Canada at 30 days (18.9%) and at one year (32.0%). Data was not presented by stroke type or by age or gender. The ratio of one-year mortality to 30-day mortality reported in this study can be estimated as 1.78 (0.32/0.189). In the model, this factor was applied to the 28 mortality rates reported by Johansen et al. [37] in order to estimate one-year age and gender specific mortality rates for ischemic stroke. For poststroke mortality after one year, general population mortality was increased by a factor of 2.3. This was based on a long-term population-based stroke study [39]. Mortality after ICH was estimated in a similar manner. Thirty-day age and gender specific
mortality after intracranial hemorrhage (ICH) (ICD9-431) was taken from the Canadian-based study by Johansen et al. [37]. To estimate one-year mortality, the 30-day mortality rates were increased by a factor of 1.2. This adjustment factor was based on a study on long-term mortality post-ICH [40]. Flaherty et al. [40, 41] reported mortality to be 0.48 and 0.59 at one month and one year, respectively.

2.10. Utilities. While being in the normal sinus rhythm health state, patients were assigned age and gender specific general population utility values [42]. No existing published studies primarily reporting utilities for AF were identified. However, Reynolds et al. [43] do describe various utility studies primarily reporting utilities for AF were identified. The general population utility values [42] included over 1000 patients with a first time diagnosis of AF. Reynolds et al. [43] reported the average change in utility moving from an AF to NSR health state, as the other studies evaluated intervention specific changes in utility values.

Utility weights were estimated for both ischemic and haemorrhagic stroke. Data from two studies were used to derive stroke health state utility weights. Riviero-Arias et al. [45] provided estimates of poststroke utility scores according to modified Rankin Score (mRS). In a Canadian-based cohort study, Goeree et al. [46] reported the distribution of discharge modified ranking score according to the type of stroke (ischemic, haemorrhagic, and transient ischemic attack). The mRS specific utility values reported by Riviero-Arias et al. [45] were applied to the distribution of hospital discharge mRS reported by Goeree et al. in order to derive a weighted average utility weight for ischemic and haemorrhagic stroke. Based on this data, the utility weight applied to patients after ischemic and haemorrhagic stroke was 0.46 and 0.28, respectively.

A disutility of 1.0 for seven days was applied to the AF ablation complications. For pulmonary toxicity, a disutility of 1.0 for the duration of a related hospitalization was applied. The mean length of stay for a pulmonary toxicity related hospitalization was estimated to be 13 days. This was based on hospitalizations identified from the Ontario Case Costing Initiative database [47] with a primary diagnosis of J70.2 (acute drug-induced interstitial lung disorders), J70.3 (chronic drug-induced interstitial lung disorders), J70.4 (respiratory conditions due to drug-induced interstitial lung disorders, unspecified), or J84.1 (idiopathic pulmonary fibrosis). For irreversible pulmonary toxicity, a utility weight of 0.6 was applied to each cycle [48].

2.11. Cost of Ablation Procedure. The cost of an entire inpatient stay for an ablation procedure was estimated using data from the Ontario Case Costing project [47]. We specifically used the average cost of hospitalizations with a primary procedure code indicating catheter ablation using a percutaneous transluminal approach (1.HH.59.GP-AW) and the most responsible diagnosis of atrial fibrillation (1480). Based on these criteria, the mean cost per AF ablation hospitalization was estimated to be $7,056. The physician fees for an AF ablation procedure were estimated using expert opinion on applicable physician fee codes and fees listed in the Ontario schedule of benefits for physician services [49]. The total physician fees for an AF ablation procedure were estimated to be $2,534. The total cost per AF ablation used in the model was $9,590. The number of ablation procedures per patient was derived from a survey of electrophysiology laboratories published by Cappato et al. [50]. Cappato et al. reported that amongst 8745 AF ablation patients, 2389 (27%) required one or more ablation procedures. Therefore, in the model it was assumed that each patient would require 1.27 ablation procedures and the total procedure costs applied to the AF-ablation arm were $12,179 ($9,590 × 1.27). In the first year after ablation, patients were assumed to be followed up with three cardiologist consultations and undergo a CT scan during the first year after ablation. The cumulative cost of followup in the first-year follow-up was $666. No follow-up costs were applied after the first year after ablation.

2.12. Procedural Complication Costs. The cost of procedural complications was estimated from a published Canadian-based costing study by Khaykin et al. [51]. The unit costs of cardiac tamponade, PV stenosis, stroke, and transient ischemic attack specifically were $5,842, $8,487, $14,187, and $4,297, respectively. These costs included inflation to 2010 SCND using the healthcare component of the consumer price index. The acute cost of pulmonary toxicity was estimated from the Ontario Case Costing Initiative. The mean cost per hospitalization with a primary diagnosis potentially related to pulmonary toxicity was found to be $20,436. These were hospitalizations with a primary diagnosis code of J70.2 (acute drug-induced interstitial lung disorders), J70.3 (chronic drug-induced interstitial lung disorders), J70.4 (respiratory conditions due to drug-induced interstitial lung disorders, unspecified), or J84.1 (idiopathic pulmonary fibrosis). For irreversible pulmonary toxicity, an annual cost of $3,799 was applied [52]. These costs included inflation to 2010 SCND using the healthcare component of the consumer price index [53].

2.13. Medication Costs. Unit costs for medications were based on reimbursement prices from the Ontario Drug Benefit Formulary [54]. The assumed daily dose of amiodarone was 200 mg per day. An 8% pharmacy markup was applied to the raw drug costs along with a $7.00 dispensing fee. It was assumed that a 90-day supply of the drug would be dispensed each time. The total annual cost of amiodarone was estimated to be $433.29. Both patients with normal sinus rhythm and
those in the AF health state were assigned amiodarone costs each cycle.

The assumed daily dose of warfarin was 5 mg per day. An 8% pharmacy markup was applied to the raw drug costs along with a $7.00 dispensing fee. It was assumed that a 90-day supply of the drug would be dispensed each time. The total annual warfarin cost used in the model was $753.30. In addition, an annual monitoring cost for warfarin of $387.54 was assumed in the model [55]. This cost included inflation to 2010 $CDN using the healthcare component of the consumer price index [40, 53].

2.14. Stroke and Major Bleed Costs. The cost of stroke was estimated from a Canadian-based costing study by Goeree et al. [46]. In this study, the total one year health care cost for patients suffering an ischemic stroke was found to be $53,576. The one year cost following a haemorrhagic stroke was estimated to be $56,573. These costs were applied to the first year after stroke in the current model. Goeree et al. presented stroke costs by different resource categories. Costs for the second year and after stroke were assumed to be equal to the sum of the costs for long-term care, home care, prescription medications, outpatient visits, doctor visits, and assistive devices. These costs amounted to $6,265 and $4,841 for ischemic and haemorrhagic stroke, respectively. After inflating to 2010 $CDN [53], the first-year costs for ischemic and haemorrhagic were $61,413 and $58,159, respectively. Each subsequent year’s costs for ischemic and haemorrhagic stroke were $6,801 and $5,843, respectively. The cost of a major bleed used in the model was $6,023 and was based on the average cost of a hospitalization with a case mix group for a gastrointestinal bleed (CMG 281).

2.15. Variability and Uncertainty. Parameter uncertainty is evaluated using probabilistic sensitivity analysis (PSA) and is presented in the form of a cost-effectiveness acceptability curve for the AF ablation strategy. One thousand Monte Carlo simulations were used in the PSA. Table 2 presents the distributions, parameters, and resultant 95% confidence intervals for model parameters.

Model structural uncertainty was assessed using one-way sensitivity analysis. Cost-effectiveness specifically results presented are varying discount rates, model time horizon, the annual probability of AF recurrence after ablation, and the disutility of being in the AF health state. Additionally, the model was run under the assumption that restoration of NSR does not impact the stroke risk and under the assumption that amiodarone treatment is discontinued for patients not in normal sinus rhythm.

Variability of different patient groups was also assessed using one way sensitivity analyses. Model results according to age and gender were tested along with model results by baseline CHADS2 stroke risk score. Sensitivity analysis on age and gender was conducted under two scenarios. In the first scenario, the same probability of stroke was assumed for all age groups. The probability of stroke was the same for all ages given a specific CHADS2 score. In the second scenario, the risk of stroke is varied according to age using Framingham stroke risk data [56]. Wolf et al. [56] presented the 10-year risk of stroke according to age and gender. Using this data, the relative risk for stroke for different ages relative to 65 year olds was estimated and applied to the risk of stroke based on a CHADS2 risk score of 2.

3. Basecase Results

Table 3 presents the cost-effectiveness results for the base-case analysis. As shown, the ablation treatment group was estimated to incur $8,539 in incremental expected costs compared to the AAD treatment group. The model estimated that the ablation group had more expected QALYs and fewer expected number of strokes compared to the AAD treatment group. The ablation treatment arm specifically was estimated to result in 0.033 fewer expected number of strokes and 0.144 more quality adjusted life years compared to the AAD treatment arm. Based on the expected costs and QALYs estimated by the model, the incremental cost per QALY of the ablation arm compared to the AAD arm is $59,194. Therefore, using the basecase analysis, ablation would be considered cost-effective if societies’ willingness to pay for a QALY is $59,194 or higher. Otherwise, AAD therapy is the cost-effective treatment strategy.

Figure 3 presents the cost-effectiveness acceptability curve for the AF ablation strategy compared to the AAD strategy. AF ablation has the highest probability of being cost-effective at willingness to pay values of $62,000 per QALY and higher. The probability of AF ablation being cost-effective at willingness to pay for a QALY threshold of $25,000, $50,000, $100,000, and $150,000 was estimated to be 0.03, 0.30, 0.89, and 0.98, respectively.

4. One-Way Sensitivity Analysis

Table 4 presents cost-effectiveness results for different patient groups based on age, gender, and CHADS2 index score. As shown, cost-effectiveness results varied according to age and
Table 2: Distributions used for model parameters in probabilistic sensitivity analysis.

| Variable                                                                 | Distribution (parameters)                      | Mean   | 95% C.I. based on distribution and parameters |
|--------------------------------------------------------------------------|-------------------------------------------------|--------|-----------------------------------------------|
| **Normal sinus rhythm (NSR) variables**                                   |                                                 |        |                                               |
| Probability of remaining in normal sinus rhythm at 1 year for AAD         | Beta (α = 26.47, β = 176.11)                    | 0.26   | (0.17, 0.34)                                  |
| RR of NSR at 1 year with ablation                                        | log normal (exp(μ = 1.07, s.e. = 0.18))        | 2.93   | (2.09, 4.11)                                  |
| Probability (annual) of AF recurrence after NSR with AAD                 | Beta (α = 20.71, β = 550.23)                    | 0.036  | (0.00324, 0.00904)                            |
| Probability (annual) of AF recurrence after NSR with ablation            | Beta (α = 122.53, β = 431.47)                   | 0.221  | (0.023, 0.053)                                 |
| Disutility due to AF                                                    | Beta (4.6, 95.4)                                | 0.046  | (0.014, 0.095)                                 |
| **Treatment cost variables**                                             |                                                 |        |                                               |
| Annual cost of Amiodarone                                               | Fixed                                           | $433   |                                               |
| Cost of AF ablation hospitalization                                      | Gamma (25, 282.24)                              | $7,056 | ($4566, $10,709)                              |
| AF ablation physician fees                                              | Fixed                                           | $2534  |                                               |
| Number of AF ablation procedures                                         | Fixed                                           | 1.27   |                                               |
| Follow-up cost 1st year after ablation                                   | Fixed                                           | $666   |                                               |
| **Perioperative ablation complication variables**                        |                                                 |        |                                               |
| Probability of stroke as complication of AF ablation                    | Beta (α = 17, β = 5648)                         | 0.003  | (0.0017, 0.0046)                              |
| Probability of TIA as complication of AF ablation                       | Beta (α = 13, β = 5454)                         | 0.002  | (0.0012, 0.0038)                              |
| Probability of cardiac tamponade as complication of AF ablation         | Beta (α = 45, β = 5678)                         | 0.008  | (0.0057, 0.0010)                              |
| Probability of PV stenosis as complication of AF ablation               | Beta (α = 91, β = 5740)                         | 0.016  | (0.0017, 0.0049)                              |
| Cost of stroke as complication from AF ablation                         | Gamma (α = 25, β = 594.88)                      | $14872 | ($9624, $21243)                               |
| Cost of TIA as complication from AF ablation                            | Gamma (α = 25, β = 171.87)                      | $4296  | ($2,781, $6137)                               |
| Cost of cardiac tamponade as complication from AF ablation              | Gamma (α = 25, β = 233.69)                      | $5842  | ($3781, $8345)                                |
| Cost of PV stenosis as complication from AF ablation                    | Gamma (α = 25, β = 339.47)                      | $8487  | ($5492, $12123)                               |
| **Pulmonary toxicity variables**                                         |                                                 |        |                                               |
| Annual probability of pulmonary toxicity                                 | Beta (6.14, 731.86)                             | 0.008  | (0.003, 0.016)                                |
| Probability of death from pulmonary toxicity                             | Beta (3, 30)                                   | 0.091  | (0.019, 0.208)                                |
| Probability that pulmonary toxicity is irreversible                      | Beta (25, 75)                                  | 0.25   | (0.171, 0.338)                                |
| Cost of acute pulmonary toxicity                                         | Gamma (25, 897.36)                             | $22434 | ($14518, $32044)                              |
| Annual cost of irreversible pulmonary toxicity                           | Gamma (α = 25, β = 151.98)                      | $3799  | ($2459, $5427)                                |
| Utility weight for irreversible pulmonary toxicity                       | Beta (60, 40)                                  | 0.6    | (0.503, 0.693)                                |
| **Ischemic stroke variables**                                            |                                                 |        |                                               |
| Annual probability of stroke (Chads2 = 2)                               | Beta (α = 58.97, β = 1415.21)                   | 0.04   | (0.031, 0.051)                                |
| Increase in risk of stroke in the presence of AF                        | log normal (exp(μ = 0.47, s.e. = 0.18))         | 1.6    | (1.11, 2.30)                                  |
| First year cost of ischemic stroke                                       | Gamma (α = 25, β = 2326.39)                     | $58159 | ($37638, $83076)                              |
| Subsequent years of ischemic stroke                                      | Gamma (α = 25, β = 272.2)                       | $6801  | ($4401, $9715)                                |
| Utility weight for ischemic stroke                                       | Beta (91.19, 108.80)                            | 0.46   | (0.39, 0.53)                                  |
| **Anticoagulation variables**                                            |                                                 |        |                                               |
| Proportion of patients on warfarin                                       | Beta (442.2, 562.8)                             | 0.44   | (0.408, 0.471)                                |
| Annual cost of warfarin treatment and monitoring                        | Fixed                                           | $463   |                                               |
| Annual probability of major bleed while being on placebo                 | Beta (15, 2579.6)                               | 0.0058 | (0.00324, 0.00904)                            |
| Relative risk of major bleed warfarin relative to placebo                | log normal (exp(μ = −0.798, s.e. = 0.306))      | 0.45   | (0.25, 0.82)                                  |
| Proportion of major bleeds that are ICH                                   | Beta (966.96, 1942.04)                          | 0.33   | (0.315, 0.350)                                |
| First year cost of hemmorhagic stroke                                     | Gamma (α = 25, β = 2456.53)                     | $61413 | ($39743, $87723)                              |
| Cost for subsequent years of hemmorhagic stroke                           | Gamma (α = 25, β = 210.10)                      | $5255  | ($3401, $7507)                                |
| Utility weight for hemorrhagic stroke                                     | Beta (55.38, 144.62)                            | 0.28   | (0.22, 0.34)                                  |
Table 3: Basecase cost-effectiveness results.

| Treatment                  | Expected costs | Expected strokes | Expected QALYs | $/QALY  |
|----------------------------|----------------|------------------|----------------|---------|
| Ablation                   | $21,150        | 0.122            | 3.416          |         |
| AAD                        | $12,611        | 0.155            | 3.272          |         |
| Incremental (Ablation-AAD) | $8,539         | 0.033            | 0.144          | $59,194 |

Table 4: One-way sensitivity analyses.

| Sensitivity analysis by age and gender assuming the same risk of stroke for all starting ages | Incremental costs | Incremental QALYs | Incremental $/QALY |
|-------------------------------------------------------------------------------------------|------------------|------------------|-------------------|
| **Males**                                                                                 |                  |                  |                   |
| Age                                                                                      |                  |                  |                   |
| 55                                        | $8,330           | 0.146            | $57,088           |
| 60                                        | $8,365           | 0.145            | $57,765           |
| 65                                        | $8,539           | 0.144            | $59,194           |
| 70                                        | $8,630           | 0.141            | $61,120           |
| 75                                        | $8,787           | 0.135            | $65,129           |
| **Females**                                                                               |                  |                  |                   |
| Age                                                                                      |                  |                  |                   |
| 55                                        | $8,330           | 0.146            | $57,088           |
| 60                                        | $8,365           | 0.145            | $57,765           |
| 65                                        | $8,548           | 0.144            | $59,219           |
| 70                                        | $8,637           | 0.141            | $61,142           |
| 75                                        | $8,793           | 0.135            | $65,147           |
| **CHADS2 risk score**                                                                    |                  |                  |                   |
| 0                                          | $9,259           | 0.135            | $68,822           |
| 1                                          | $8,941           | 0.139            | $64,412           |
| 2                                          | $8,539           | 0.144            | $59,194           |
| 3                                          | $7,952           | 0.152            | $52,214           |
| 4                                          | $7,242           | 0.162            | $44,652           |
| **Time horizon**                                                                         |                  |                  |                   |
| 3 years                                    | $10,670          | 0.082            | $130,711          |
| 5 years                                    | $8,539           | 0.144            | $59,194           |
| 10 years                                   | $4,299           | 0.301            | $14,273           |
| 20 years                                   | ($71)            | 0.505            | AF ablation dominates |
| **Discount rate**                                                                        |                  |                  |                   |
| 0%                                         | $7,995           | 0.162            | $49,308           |
| 3%                                         | $8,335           | 0.151            | $55,211           |
| 5%                                         | $8,539           | 0.144            | $59,194           |
| Restoring NSR has no impact on stroke risk    | $10,019          | 0.116            | $86,129           |
| **Disutility of AF health state**                                                          |                  |                  |                   |
| 0                                          | $8,539           | 0.038            | $221,839          |
| 0.02                                       | $8,539           | 0.084            | $101,083          |
| 0.04                                       | $8,539           | 0.130            | $65,454           |
| 0.06                                       | $8,539           | 0.176            | $48,396           |
| 0.08                                       | $8,539           | 0.222            | $38,390           |
| **Annual probability of recurrence of AF after ablation**                                 |                  |                  |                   |
| 0.00                                       | $8,230           | 0.153            | $53,831           |
| 0.01                                       | $8,317           | 0.150            | $55,276           |
| 0.02                                       | $8,403           | 0.148            | $56,743           |
| 0.03                                       | $8,486           | 0.146            | $58,233           |
| 0.04                                       | $8,569           | 0.143            | $59,745           |
| 0.05                                       | $8,650           | 0.141            | $61,280           |
The incremental cost per QALY is estimated to be $57,088 for a 55-year-old female and $65,129 for 75-year-old female. For males, the incremental cost per QALY was estimated to be $57,167 for a 55 year old and $65,129 for a 75 year old. Cost-effectiveness results did vary according to the CHADS index score. When the CHADS index score for the model cohort is 0, the incremental cost per QALY of ablation compared to AAD becomes $68,822. When the CHADS index score was 4, the incremental cost per QALY became $44,652. The time horizon chosen had a large impact on results. Using a 10-year time horizon, the incremental cost per QALY became $14,273 for AF ablation compared to AAD. A 20-year time horizon results in ablation being both less costly and more effective than the AAD treatment strategy. Discount rates had a relatively small impact on results. If a zero percent discount rate is used, the incremental cost per QALY of the ablation strategy became $49,308 per QALY. In their economic evaluation of ablation compared to AAD, Reynolds et al. assumed that restoration of NSR had no impact on the risk of stroke. If this same assumption is applied in the current model, the cost per QALY of the AF ablation strategy became $86,129. As shown, even with the assumption that restoration of NSR does not impact stroke risk, the incremental QALYs from AF ablation were only reduced from 0.144 in the basecase to 0.116. This indicates that much of the difference in QALYs predicated by the model was due to the disutility applied to patients while in the AF health state. If the disutility of being in AF compared to NSR is 0.08 instead of the basecase value of 0.043, the cost per QALY of AF ablation becomes $38,390 per QALY. If the disutility of being in the AF health state is 0.02 or 0.00 the incremental cost per QALY becomes $101,083 per QALY and $221,839 per QALY, respectively. The annual probability of recurrence of AF in patients undergoing ablation has little impact on the cost per QALY estimate. If the annual probability of AF recurrence is assumed to be 0.00, the cost per QALY becomes $53,831. If the annual probability of AF recurrence is assumed to be 0.05, the cost per QALY becomes $61,280.

5. Discussion

The current study found the incremental cost per QALY of catheter ablation of AF to be $59,194 in Canada compared to treatment with Amiodarone in patients previously failing an antiarrhythmic medication. Based on common cost-effectiveness thresholds, this may be considered to be a cost-effective strategy. Our findings are similar to those from economic evaluations of AF ablation conducted from the perspective of other countries. McKenna et al. [57] evaluated the cost-effectiveness of AF ablation compared to treatment with Amiodarone from a UK perspective. The authors assumed a lifelong time horizon in their basecase and estimated the cost-effectiveness of AF ablation to be £7,910 per QALY for patients with a CHADS risk score of 3. Assuming a 5-year time horizon, the cost-effectiveness of AF ablation in this patient group was estimated to be £20,831 ($Can32,704). Reynolds et al. [43] conducted a US-based economic evaluation of catheter ablation for AF compared to treatment with Amiodarone in the same population as our study. Using a 5-year time horizon theoretical basecase, the authors estimated the cost per QALY of ablation compared to amiodarone to be $51,131. It is worth noting that Reynolds et al. [43] assumed no benefit of ablation on the subsequent risk of stroke. Therefore, the increase in QALYs was primarily due to better quality of life after ablation. Our study is unique because it is the first to look at the cost-effectiveness of catheter ablation from a Canadian perspective.

There are a number of limitations to this study. One limitation is that the published RCT comparing the proportion of patients achieving normal sinus rhythm after ablation or antiarrhythmic drugs is limited to 1 year followup. Assumptions had to be made on the effectiveness of the two strategies on maintaining rhythm control beyond the first year. Additionally, no published data was found directly comparing stroke rates between patients treated with ablation compared to those treated with AAD.

References

[1] A. D. Krahn, J. Manfreda, R. B. Tate, F. A. L. Mathewson, and T. E. Cuddy, “The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study,” American Journal of Medicine, vol. 98, no. 5, pp. 476–484, 1995.

[2] A. S. Go, E. M. Hylek, K. A. Phillips et al., “Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study,” Journal of the American Medical Association, vol. 285, no. 18, pp. 2370–2375, 2001.

[3] G. Y. H. Lip and C. J. Boos, “Antithrombotic treatment in atrial fibrillation,” Heart, vol. 92, no. 2, pp. 155–161, 2006.

[4] K. H. Humphries, C. Jackevicius, Y. Gong et al., “Population rates of hospitalization for atrial fibrillation/flutter in Canada,” Canadian Journal of Cardiology, vol. 20, no. 9, pp. 869–876, 2004.

[5] V. Fuster, L. E. Ryden, D. S. Cannom et al., “ACC/AHA/ESC, 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society,” Circulation, vol. 114, no. 7, pp. e257–e354, 2006.

[6] “2004 Canadian Cardiovascular Society Consensus Conference: atrial fibrillation,” Canadian Journal of Cardiology, vol. 21, supplement B, pp. 9B–73B, 2005.

[7] V. Fuster, L. E. Rydén, D. S. Cannom et al., “ACC/AHA/ESC, 2006 guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society,” Journal of the American College of Cardiology, vol. 48, no. 4, pp. e149–e246, 2006.
[8] K. H. Humphries, C. R. Kerr, M. Steinbuch, and P. Dorian, “Limitations to antiarrhythmic drug use in patients with atrial fibrillation,” CMAJ, vol. 171, no. 7, pp. 741–745, 2004.

[9] H. Calkins, J. Brugada, D. L. Packer et al., “HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for personnel, policy, procedures and follow-up. A report of the Heart Rhythm Society (HRS) task force on catheter and surgical ablation of atrial fibrillation. Developed in partnership with the European Heart Rhythm Association (EHRA),” Heart Rhythm, vol. 4, no. 6, pp. 816–861, 2007.

[10] National Collaborating Centre for Chronic Conditions, Atrial Fibrillation: National Clinical Guideline for Management in Primary and Secondary Care, Royal College of Physicians, London, UK, 2006, http://www.nice.org.uk/nicemedia/live/10982/30055/30055.pdf.

[11] J. L. Cox and T. M. Sundt III, “The surgical management of atrial fibrillation,” Annual Review of Medicine, vol. 48, pp. 511–523, 1997.

[12] J. L. Cox, R. D. B. Jaquiss, R. B. Schuessler, and J. P. Boineau, “Modification of the maze procedure for atrial flutter and atrial fibrillation. II. Surgical technique of the maze III procedure,” Journal of Thoracic and Cardiovascular Surgery, vol. 110, no. 2, pp. 485–495, 1995.

[13] J. Dewire and H. Calkins, “State-of-the-art and emerging technologies for atrial fibrillation ablation,” Nature Reviews Cardiology, vol. 7, no. 3, pp. 129–138, 2010.

[14] J. Cheng and M. F. Arnsdorf, “Radiofrequency catheter ablation to prevent recurrent atrial fibrillation,” in UpToDate, UpToDate, Waltham, Mass, USA, 2009.

[15] Australian Safety and Efficacy Register of New Interventional Procedures-Surgical (ASERNIP-S), Minimally Invasive Surgical Technologies for Atrial Fibrillation, Royal Australasian College of Surgeons, East Melbourne, Australia, 2008, http://www.health.gov.au/internet/horizon/publishing.nsf/Content/E76DDEECD7BDA8CA2575AD0080F341/SFile/PRIORITISING%20SUMMARY-Minimally%20invasive%20treatment%20atrial%20fibrillation.pdf

[16] “Ablation for atrial fibrillation: an evidence-based analysis,” Ontario Health Technology Assessment Series, vol. 6, no. 7, pp. 1–63, 2006, http://www.hqontario.ca/english/providers/program/mas/tech/reviews/pdf/rev_ao30106.pdf.

[17] B. F. Gage, A. D. Waterman, W. Shannon, M. Boechler, M. W. Rich, and M. J. Radford, “Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation,” Journal of the American Medical Association, vol. 285, no. 22, pp. 2864–2870, 2001.

[18] N. Assasi, G. Blackhouse, F. Xie et al., “Ablation procedures for rhythm control in patients with atrial fibrillation: clinical and cost-effectiveness analyses,” Tech. Rep. 128, Canadian Agency for Drugs and Technologies in Health, Ottawa, Canada, 2010, http://www.cadth.ca/media/pdf/H0491_Ablation_Procedures_with_Atrial_Fibrillation_tr_e.pdf

[19] G. B. Forleo, M. Mantica, L. de Luca et al., “Catheter ablation of atrial fibrillation in patients with diabetes mellitus type 2: results from a randomized study comparing pulmonary vein isolation versus antiarrhythmic drug therapy,” Journal of Cardiovascular Electrophysiology, vol. 20, no. 1, pp. 22–28, 2009.

[20] P. Jais, B. Cauchemez, L. Macle et al., “Catheter ablation versus antiarrhythmic drugs for atrial fibrillation: the A4 study,” Circulation, vol. 118, no. 24, pp. 2498–2505, 2008.

[21] R. Krittayaphong, O. Raungrattanapan, K. Bhuripanyo et al., “A randomized clinical trial of the efficacy of radiofrequency catheter ablation and amiodarone in the treatment of symptomatic atrial fibrillation,” Journal of the Medical Association of Thailand, vol. 86, supplement 1, pp. 58–516, 2003.

[22] C. Pappone, G. Augello, S. Sala et al., “A randomized trial of circumferential pulmonary vein ablation versus antiarrhythmic drug therapy in paroxysmal atrial fibrillation. The APAF study,” Journal of the American College of Cardiology, vol. 48, no. 11, pp. 2340–2347, 2006.

[23] D. J. Wilber, C. Pappone, P. Neuzil et al., “Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial,” Journal of the American Medical Association, vol. 303, no. 4, pp. 333–340, 2010.

[24] R. DerSimonian and N. Laird, “Meta-analysis in clinical trials,” Controlled Clinical Trials, vol. 7, no. 3, pp. 177–188, 1986.

[25] D. G. Sherman, S. G. Kim, B. S. Boop et al., “Occurrence and characteristics of stroke events in the Atrial Fibrillation Follow-Up Investigation of Sinus Rhythm Management (AFFIRM) study,” Archives of Internal Medicine, vol. 165, no. 10, pp. 1185–1191, 2005.

[26] M. R. Reynolds, J. Shah, V. Essebag et al., “Patterns and predictors of Warfarin use in patients with new-onset atrial fibrillation from the FRACTAL registry,” American Journal of Cardiology, vol. 97, no. 4, pp. 538–543, 2006.

[27] G. Y. H. Lip and S. J. Edwards, “Stroke prevention with aspirin, warfarin and ximelagatran in patients with non-valvular atrial fibrillation: a systematic review and meta-analysis,” Thrombosis Research, vol. 118, no. 3, pp. 321–333, 2006.

[28] R. McBride, “Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: stroke prevention in atrial fibrillation II study,” The Lancet, vol. 343, no. 8899, pp. 687–691, 1994.

[29] “Bleeding during antithrombotic therapy in patients with atrial fibrillation. The Stroke Prevention in Atrial Fibrillation investigators,” Archives of Internal Medicine, vol. 156, no. 4, pp. 409–416, 1996.

[30] C. Pappone, S. Rosanio, G. Augello et al., “Mortality, morbidity, and quality of life after circumferential pulmonary vein ablation for atrial fibrillation: outcomes from a controlled nonrandomized long-term study,” Journal of the American College of Cardiology, vol. 42, no. 2, pp. 185–197, 2003.

[31] H. Calkins, M. R. Reynolds, P. Spector et al., “Treatment of atrial fibrillation with antiarrhythmic drugs or radiofrequency ablation: two systematic literature reviews and meta-analyses,” Circulation, vol. 2, no. 4, pp. 349–361, 2009.

[32] V. R. Vorperian, T. C. Havighurst, S. Miller, and C. T. Janway, “Adverse effects of low dose amiodarone: a meta-analysis,” Journal of the American College of Cardiology, vol. 30, no. 3, pp. 791–801, 1997.

[33] D. K. Owens, G. D. Sanders, R. A. Harris et al., “Cost-effectiveness of implantable cardioverter defibrillators relative to amiodarone for prevention of sudden cardiac death,” Annals of Internal Medicine, vol. 126, no. 1, pp. 1–12, 1997.

[34] R. E. Dusman, M. S. Stanton, W. M. Miles et al., “Clinical features of amiodarone-induced pulmonary toxicity,” Circulation, vol. 82, no. 1, pp. 51–59, 1990.

[35] Statistics Canada, Life Tables, Canada, Provinces and Territories, 2000–2002, Table 2b Complete Life Table, Canada, 2000 To 2002: Females, Statistics Canada, Ottawa, Canada, http://www.statcan.gc.ca/pub/84-537-x/t/pdf/419861-eng.pdf.
[36] Statistics Canada, *Life Tables, Canada, Provinces and Territories, 2000–2002, Table 2b Complete Life Table, Canada, 2000 To 2002: Males*, Statistics Canada, Ottawa, http://www.statcan.gc.ca/pub/84-537-x/t/pdf/4198612-eng.pdf.

[37] H. L. Johansen, A. T. Wielgosz, K. Nguyen, and R. N. Fry, “Incidence, comorbidity, case fatality and readmission of hospitalized stroke patients in Canada,” *Canadian Journal of Cardiology*, vol. 22, no. 1, pp. 65–71, 2006.

[38] J. V. Tu and Y. Gong, “Trends in treatment and outcomes for acute stroke patients in Ontario, 1992–1998,” *Archives of Internal Medicine*, vol. 163, no. 3, pp. 293–297, 2003.

[39] K. Hardie, G. J. Hankey, K. Jamrozik, R. J. Broadhurst, and C. Anderson, “Ten-year survival after first-ever stroke in the Perth community stroke study,” *Stroke*, vol. 34, no. 8, pp. 1842–1846, 2003.

[40] Statistics Canada, *Inflation Rate Calculations*, Statistics Canada, Ottawa, Canada, 2010.

[41] M. L. Flaherty, M. Haverbusch, P. Sekar et al., “Long-term mortality after intracerebral hemorrhage,” *Neurology*, vol. 66, no. 8, pp. 1182–1186, 2006.

[42] P. Kind, G. Hardman, and S. Macran, *UK Population Norms For EQ-5D*, Center for Health Economics, University of York, York, UK, 1999, http://www.york.ac.uk/inst/che/pdf/DP172.pdf.

[43] M. R. Reynolds, P. Zimetbaum, M. E. Josephson, E. Ellis, T. Danilow, and D. J. Cohen, “Cost-effectiveness of radiofrequency catheter ablation compared with antiarrhythmic drug therapy for paroxysmal atrial fibrillation,” *Circulation*, vol. 2, no. 4, pp. 362–369, 2009.

[44] J. E. Brazier and J. Roberts, “The estimation of a preference-based measure of health from the SF-12,” *Medical Care*, vol. 42, no. 9, pp. 851–859, 2004.

[45] O. Rivero-Arias, M. Ouellet, A. Gray, J. Wolstenholme, P. M. Rothwell, and R. Luengo-Fernandez, “Mapping the modified rankin scale (mRS) measurement into the generic EuroQol (EQ-5D) health outcome,” *Medical Decision Making*, vol. 30, no. 3, pp. 341–354, 2010.

[46] R. Goeree, G. Blackhouse, R. Petrovic, and S. Salama, “Cost of stroke in Canada: a one-year prospective study,” *Journal of Medical Economics*, vol. 8, pp. 147–167, 2005.

[47] Ontario Case Costing Initiative (OCCI), *OCCI Costing Analysis Tool*, Ontario Case Costing Initiative, Toronto, Canada, 2010, http://www.o FCCp.com/.

[48] E. Catherwood, W. D. Fitzpatrick, M. L. Greenberg et al., “Cost-effectiveness of cardioversion and antiarrhythmic therapy in nonvalvular atrial fibrillation,” *Annals of Internal Medicine*, vol. 130, no. 8, pp. 625–636, 1999.

[49] Ministry of Health and Long-Term Care (Ontario), *Schedule of Benefits for Physician Services Under the Health Insurance Act: Effective*, The Ministry, Toronto, Canada, 2009, http://www.health.gov.on.ca/english/providers/program/ohip/sob/physerv/physerv_mm.html.

[50] R. Cappato, H. Calkins, S. A. Chen et al., “Worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation,” *Circulation*, vol. 111, no. 9, pp. 1100–1105, 2005.

[51] Y. Khaykin, C. A. Morillo, A. C. Skanes, A. McCracken, K. Humphries, and C. R. Kerr, “Cost comparison of catheter ablation and medical therapy in atrial fibrillation,” *Journal of Cardiovascular Electrophysiology*, vol. 18, no. 9, pp. 907–913, 2007.